Literature DB >> 25546753

Peripheral neuropathies: current evidence for alternative treatment regimens and treatment combinations.

C Sommer1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25546753      PMCID： PMC4285482          DOI： 10.1111/cei.12502

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  19 in total

1.  Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study.

Authors:  M P J Garssen; R van Koningsveld; P A van Doorn; I S J Merkies; M Scheltens-de Boer; J A van Leusden; I N van Schaik; W H J P Linssen; F Visscher; A M Boon; C G Faber; J Meulstee; M J J Prick; L H van den Berg; H Franssen; J A P Hiel; P Y K van den Bergh; C J M Sindic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-09       Impact factor: 10.154

Review 2.  Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Filip Eftimov; John B Winer; Marinus Vermeulen; Rob de Haan; Ivo N van Schaik
Journal:  Cochrane Database Syst Rev       Date:  2013-12-30

3.  Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.

Authors: 
Journal:  Lancet       Date:  1997-01-25       Impact factor: 79.321

Review 4.  Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Man Mohan Mehndiratta; Richard A C Hughes
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

Review 5.  Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes; Man Mohan Mehndiratta
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

Review 6.  Corticosteroids for Guillain-Barré syndrome.

Authors:  Richard A C Hughes; Pieter A van Doorn
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

7.  Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  R Hughes; S Bensa; H Willison; P Van den Bergh; G Comi; I Illa; E Nobile-Orazio; P van Doorn; M Dalakas; M Bojar; A Swan
Journal:  Ann Neurol       Date:  2001-08       Impact factor: 10.422

8.  Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy.

Authors:  B Tackenberg; J D Lünemann; A Steinbrecher; E Rothenfusser-Korber; M Sailer; W Brück; S Schock; R Zschenderlein; F Zipp; N Sommer
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

9.  Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.

Authors:  R van Koningsveld; P I M Schmitz; F G Avander Meché; L H Visser; J Meulstee; P A van Doorn
Journal:  Lancet       Date:  2004-01-17       Impact factor: 79.321

10.  Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial.

Authors:  Sanne Piepers; Renske Van den Berg-Vos; W-Ludo Van der Pol; Hessel Franssen; John Wokke; Leonard Van den Berg
Journal:  Brain       Date:  2007-07-10       Impact factor: 13.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.